BeOne Medicines Ltd.

BeOne Medicines Ltd. is a global oncology company focused on discovering and developing treatments for cancer patients. In 2025, the company generated total global revenue of approximately $5.3 billion, representing an increase of approximately 40.2% from the prior year. It achieved a net income of $286.9 million, net cash provided by operating activities of $1.1 billion, and positive free cash flow of $941.7 million. BeOne Medicines specializes in hematology, having built a wholly-owned and foundational franchise. The company has assets across three foundational chronic lymphocytic leukemia (CLL) mechanisms of action (MoAs). These include BRUKINSA®, a Bruton's tyrosine kinase (BTK) inhibitor, sonrotoclax, a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). BRUKINSA was designed for complete sustainable inhibition of BTK. The ALPINE trial supported its efficacy, demonstrating sustained superior efficacy and lower cardiac toxicity in an all-comers relapsed/refractory (R/R) CLL population compared to ibrutinib. BRUKINSA is the only BTK inhibitor to prove superior efficacy to ibrutinib, particularly over the long term. It has the broadest label in its class, with U.S. approvals for CLL, mantle cell lymphoma (MCL), Waldenström's macroglobulinemia (WM), marginal zone lymphoma (MZL), and follicular lymphoma (FL). Despite being the third entrant, BRUKINSA became the global market leader across B-cell malignancies in 2025, generating $3.9 billion in sales. It is approved in over 75 markets and has launched in key markets including Europe, Japan, Korea, and Brazil. The Phase 3 MANGROVE trial is evaluating BRUKINSA plus rituximab against bendamustine plus rituximab in previously untreated MCL. Sonrotoclax, a BCL2 inhibitor, received its first global regulatory approval in December 2025. It is designed for greater potency and selectivity, with potential for better tolerability than venetoclax.